SPOTLIGHT: Novalar approval a small gain for big group

Novalar Pharmaceuticals may not have made drug history when the FDA approved their new therapy to speed the return of sensation after dental procedures, but the private biotech has some ambitious plans for marketing the drug. OraVerse goes on sale this fall at $12.50 a shot, promising to cut the amount of time spent drooling by about 75 to 85 minutes. Some people might call it trivial, but the experts say it addresses a real need. OraVerse release | Report